<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>前免疫</title><link/>https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%20%5BNLMID%5D&amp;utm_campaign= 101560960＆utm_source = chrome<description>前免疫：PubMed的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%5BNLMID%5D&amp;utm_campaign=journals&amp;utm_medium=rss&amp;ff=20250217194921&amp;v=2.18.0.post9+e462414&amp;fc=None&amp;utm_content=101560960&amp;utm_source=Chrome" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS提要（2.18.0.post9+E462414）</generator><language> en</language><lastbuilddate>周二，2025年2月18日00:49:22 +0000</lastbuilddate><pubDate> Mon, 17 Feb 2025 06:00:00 -0500</pubDate><ttl> 120</ttl><item><title>适度的定期体育锻炼可以帮助减轻血吸虫病感染对脑认知功能的系统影响</title><link/>https://pubmed.ncbi.nlm.nih.gov/39959586/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250217194921&amp;v=2.18.0.post9+e462414<description>血吸虫病的主要后果之一是它对脑功能的影响，尽管严重程度，基本的机制仍然不充分理解，突出了该疾病的知识差距。症状可能因头痛而异。此外，体育锻炼在减轻认知缺陷方面的潜在影响很少受到关注。在我们的研究中，我们利用了曼森感染的鼠模型来研究... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月31日； 15：1453742。 doi：10.3389/fimmu.2024.1453742。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">血吸虫病的主要后果之一是它对脑功能的影响，尽管严重程度，基本的机制仍然不充分理解，突出了该疾病的知识差距。症状可能因头痛而异。此外，体育锻炼在减轻认知缺陷方面的潜在影响很少受到关注。在我们的研究中，我们利用了<i>曼森</i>感染的鼠模型来研究血吸虫病的认知影响。我们的目标是多方面的：要查明成年小鼠感染期间受影响的特定认知结构域，以揭示中枢神经系统（CNS）内的神经胶质细胞和免疫细胞之间的复合物相互作用，并至关重要，以探索常规物理的潜在治疗作用。锻炼以抵消血吸虫病对中枢神经系统的有害影响。我们的发现揭示了尽管急性感染并没有破坏简单而复杂的学习或空间参考记忆，但它确实引起了回忆记忆的重大缺陷，这是认知功能的关键方面。此外，我们的研究发现了中枢神经系统内免疫和神经胶质细胞群体的深刻改变。值得注意的是，我们观察到脑膜中CD4 <sup>+</sup> T细胞和嗜酸性粒细胞的明显变化，以及海马和其他大脑区域内神经胶质细胞动力学的改变。这些改变的特征是小胶质细胞激活，星形胶质细胞反应性的降低以及朝向中枢神经系统内的促炎环境的转变。我们还提供了有关定期适度体育锻炼的变革潜力的见解，部分减轻了血吸虫病的认知和神经炎症后果。值得注意的是，运动减少了TNFα的神经胶质细胞产生，这表明向较少的促炎环境转变。总的来说，我们的研究提供了令人信服的证据，证明了血吸虫病感染与认知功能之间的复杂相互作用，强调了该领域进一步探索的关键需求。此外，我们的发现证明了体育活动对减轻血吸虫病认知负担的积极影响，为患有这种衰弱的疾病困扰的患者提供了新的希望。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39959586/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">39959586</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11825816/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">PMC11825816</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1453742>10.3389/fimmu.2024.1453742</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39959586</guid><pubDate> Mon, 17 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Inssaf Berkiks</dc:creator><dc:creator> Nada Abdel Aziz</dc:creator><dc:creator>祝福摩西</dc:creator><dc:creator>Tiroyaone Brombacher</dc:creator><dc:creator>弗兰克·布朗巴赫（Frank Brombacher）</dc:creator><dc:date> 2025-02-17</dc:date><dc:source>免疫学领域</dc:source><dc:title>适度的定期体育锻炼可以帮助减轻血吸虫病感染对脑认知功能的系统影响</dc:title><dc:identifier>PMID：39959586</dc:identifier><dc:identifier> PMC：PMC11825816</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1453742</dc:identifier></item><item><title>病例报告：JAK抑制剂治疗PTPN2缺乏患者的免疫失调症状</title><link/>https://pubmed.ncbi.nlm.nih.gov/39959585/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250217194921&amp;v=2.18.0.post9+e462414<description>最近，在几名表现出免疫失调症状的患者中，PTPN2基因中的杂合突变已被描述。该基因编码普遍存在的非受体T细胞蛋白酪氨酸磷酸酶，该酪氨酸磷酸酶对JAK-STAT途径产生负反馈。有限的临床数据提倡使用JAK抑制剂作为PTPN2缺乏症的自身免疫并发症的有效治疗方法。但是，这些并发症的发病机理的机制表明这一点... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月31日; 15：1523256。 doi：10.3389/fimmu.2024.1523256。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">最近，在几名表现出免疫失调症状的患者中， <i>PTPN2</i>基因中的杂合突变已被描述。该基因编码普遍存在的非受体T细胞蛋白酪氨酸磷酸酶，该酪氨酸磷酸酶对JAK-STAT途径产生负反馈。有限的临床数据提倡使用JAK抑制剂作为PTPN2缺乏症的自身免疫并发症的有效治疗方法。然而，这些并发症的发病机理的机理表明了这种可能性。我们报告了一名32岁的男性患有间质性肺部疾病，细胞质症和淋巴结肿大的男性患者，并在<i>PTPN2</i>中伴有<i>De-Novo</i>缺失。该患者数十年来一直接受全身类固醇治疗，这导致了激素依赖性以及与治疗相关的不良副作用。在诊断出PTPN2缺乏症后，用JAK抑制剂鲁辛尼尼进行治疗，每天以15 mg的剂量开始，每天1个月后每天升级至30 mg。类固醇治疗在3个月内停产。在9个月和16个月的检查点上，在6个月和13个月后，用李曲替尼以每天30 mg的剂量进行单一疗法后，患者的血液计数稳定，淋巴结肿大降低，肺间隙疾病得到了改善。因此，根据我们的经验，JAK抑制剂能够减轻PTPN2缺乏症状，包括血液学变化和间质性肺损伤。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39959585/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">39959585</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11825476/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">PMC11825476</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1523256>10.3389/fimmu.2024.1523256</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39959585</guid><pubDate> Mon, 17 Feb 2025 06:00:00 -0500</pubDate><dc:creator>安娜·罗佩尔特（Anna Roppelt）</dc:creator><dc:creator> Ulyana Markina</dc:creator><dc:creator> Irina Beloglazova</dc:creator><dc:creator> Vasily Parshin</dc:creator><dc:creator>德米特里·坎纳（Dmitry Kanner）</dc:creator><dc:creator> Dmitry Pershin</dc:creator><dc:creator> Mariia Fadeeva</dc:creator><dc:creator>埃琳娜·雷基纳（Elena Raykina）</dc:creator><dc:creator> Maxim Aleksenko</dc:creator><dc:creator>亚历山大·卡拉洛夫（Alexander Karaulov）</dc:creator><dc:creator>玛丽安娜·莱森科（Mariana Lysenko）</dc:creator><dc:creator>达里亚·福米纳（Daria Fomina）</dc:creator><dc:date> 2025-02-17</dc:date><dc:source>免疫学领域</dc:source><dc:title>病例报告：JAK抑制剂治疗PTPN2缺乏患者的免疫失调症状</dc:title><dc:identifier>PMID：39959585</dc:identifier><dc:identifier> PMC：PMC11825476</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1523256</dc:identifier></item><item><title>心脏手术后重症患者中脂肪酸衍生的脂质的分析产生了新型的病理生理学介质，可能与全身性炎症反应有关</title><link/>https://pubmed.ncbi.nlm.nih.gov/39959584/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250217194921&amp;v=2.18.0.post9+e462414<description>简介：重病患者患有各种临床事件，其中大多数导致促炎症状态，例如败血症或仅仅是由于大手术的结果。这些患者中的许多患者在重症监护期间会出现急性肾脏损伤，心脏或急性肝衰竭的形式。脂质信号传导与触发系统性炎症过程，疼痛和血管张力至关重要。因此，我们假设脂肪酸衍生的脂质介质可能受到调节... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月7日; 15：1148806。 doi：10.3389/fimmu.2024.1148806。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：重病患者患有各种临床事件，其中大多数导致促炎症状态，例如败血症或仅仅是由于大手术的结果。这些患者中的许多患者在重症监护期间会出现急性肾脏损伤，心脏或急性肝衰竭的形式。脂质信号传导与触发系统性炎症过程，疼痛和血管张力至关重要。因此，我们假设在炎症患者的炎症阶段和其他临床事件中可能会调节脂肪酸衍生的脂质介质，并可能是潜在的生物标志物候选者。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法和研究设计：使用液相色谱串联质谱法（LC-MS/MS），我们确定了9名患者血浆中53个脂质介质的水平。心脏手术后，这些患者在法兰克福大学医院的重症监护病房（ICU）住院。使用临床确定的生物标志物（例如白介素6（IL-6）和白细胞计数）随着时间的流逝进行了炎症阶段。脂质的正常范围值是从健康的志愿者那里获得的。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在53个脂质介质中有22个显然观察到了血浆水平，其中13个增加了（包括Ceramides CER（D18：0/18：0），CER（D18：1/16：0），CER（CER）（CER）（CER）（ D18：1/18：1），葡萄糖基 - 钙酰胺葡萄糖（D18：1/24：1），乳糖基酶laccer（D18：1/18：0）和Laccer（D18：1/24：1），6-酮-prostaglandin f1alpha（6-酮-PGF1Alpha），11,12-和14,15-DHET以及1-和2-芳基的甘油（1-AG和2-AG），鞘氨酸SPH（D18：1）和20-HETE和20-HETE 。 1），s1p（D18：0），溶血磷酸LPA（16：0），LPA（18：0），LPA（18：1）和9个hode，在增加的脂质中。 2-ag，在较低的6-酮-PGF <sub>1-α</sub>等离子体水平上显示与炎症阶段<sub>一致</sub>。至少在观察到的5例患者中，在（右）心力衰竭的所有九名患者中，在重新开放患者的胸部，实施静脉ECMO或至少会显着增加数量的情况下，所有9名患者的2AG均升高。儿茶酚胺。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">讨论：在这项试验试验中，我们确定了对危重患者的几种评估的脂质，这些脂质代表了促炎过程的潜在（病原）生理相关的介质，在心力衰竭期间，或者在心力衰竭期间，或者是在静脉血液中的静脉血液溶解之前的可能标记。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39959584/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">39959584</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11826806/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">PMC11826806</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1148806>10.3389/fimmu.2024.1148806</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39959584</guid><pubDate> Mon, 17 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Holger Neb</dc:creator><dc:creator> Verena Roth</dc:creator><dc:creator>杰西卡·罗斯（Jessica Roos）</dc:creator><dc:creator>汤姆·鲍尔</dc:creator><dc:creator>Anja Urbschat</dc:creator><dc:creator> Ulrike Heinicke</dc:creator><dc:creator> Carlo Angioni</dc:creator><dc:creator> Dieter Steinhilber</dc:creator><dc:creator> Matthias Piesche</dc:creator><dc:creator> NereaFerreirós</dc:creator><dc:creator>罗伯特·古尔克（Robert Gurke）</dc:creator><dc:creator> Gerd Geisslinger</dc:creator><dc:creator>伊迪丝·乌托奇（Edith Utech）</dc:creator><dc:creator> Kai Zacharowski</dc:creator><dc:creator>帕特里克·梅博姆（Patrick Meybohm）</dc:creator><dc:creator>帕特里克·保罗斯（Patrick Paulus）</dc:creator><dc:creator>埃尔克·施密特（Elke Schmitt）</dc:creator><dc:creator> ThorstenJürgenMaier</dc:creator><dc:date> 2025-02-17</dc:date><dc:source>免疫学领域</dc:source><dc:title>心脏手术后重症患者中脂肪酸衍生的脂质的分析产生了新型的病理生理学介质，可能与全身性炎症反应有关</dc:title><dc:identifier>PMID：39959584</dc:identifier><dc:identifier> PMC：PMC11826806</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1148806</dc:identifier></item><item><title>社论：水产养殖中的计时侵蚀性，朝向稳健而有弹性的鱼类</title><link/>https://pubmed.ncbi.nlm.nih.gov/39959583/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250217194921&amp;v=2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月31日; 15：1547738。 doi：10.3389/fimmu.2024.1547738。环保2024。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39959583/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">39959583</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11826098/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">PMC11826098</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1547738>10.3389/fimmu.2024.1547738</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39959583</guid><pubDate> Mon, 17 Feb 2025 06:00:00 -0500</pubDate><dc:creator>拜伦·莫拉莱斯 - 兰格</dc:creator><dc:creator>玛丽亚·德尔·马尔·奥尔特加 - 村民</dc:creator><dc:creator>SérgioDCRocha</dc:creator><dc:creator>露丝·蒙特罗</dc:creator><dc:creator>玛格丽斯·Øverland</dc:creator><dc:date> 2025-02-17</dc:date><dc:source>免疫学领域</dc:source><dc:title>社论：水产养殖中的计时侵蚀性，朝向稳健而有弹性的鱼类</dc:title><dc:identifier>PMID：39959583</dc:identifier><dc:identifier> PMC：PMC11826098</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1547738</dc:identifier></item><item><title> Siri和Sii作为全身性红斑狼疮中疾病活动和狼疮肾炎的潜在生物标志物</title><link/>https://pubmed.ncbi.nlm.nih.gov/39958362/?utm_source = chrome&amp;utm_medium = rsss＆utm_campaign = Journals＆campaign = 4<description>结论：SIRI和SII是SLE患者疾病活动和肾脏受累的生物标志物，可用于评估和预测SLE的发生，疾病活动和狼疮性肾炎的发生评估。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月31日； 16：1530534。 doi：10.3389/fimmu.2025.1530534。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：炎症在系统性红斑狼疮（SLE）的发展中很重要。全身性炎症反应指数（SIRI）和全身免疫炎症指数（SII）是炎症的新型临床标记，在不同疾病中具有预后价值。但是，Siri和Sii作为SLE中炎症预测因子的价值尚不清楚。这项研究探讨了Siri和SII作为SLE的潜在生物标志物。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：收集了来自280名新诊断的SLE患者和健康对照组的数据，并分为三组：没有狼疮肾炎（NLN）组（n = 93），狼疮肾炎（ln）组（n = 96）和健康对照组（n = 91）。比较了三组之间的Siri和SII差异。逻辑回归和Pearson线性分析用于分析Siri和Sii与SLE和全身性红斑狼疮疾病活动指数2000（SLEDAI-2K）的预测价值和相关性。在预测SLE，SLE疾病活动和LN方面，评估了Siri和Sii的接收器工作特性（ROC）曲线。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：与NLN组相比，LN组的SIRI和SII值明显更高（p &lt;0.01）。 SII在ROC曲线下具有预测LN的最大面积（AUC：0.6775，95％CI：0.6020-0.7531）。逻辑回归分析表明Siri和SII是LN的独立风险因素。皮尔逊线性分析表明，Siri和Sii与SLEDAI-2K（R <sub>SIRI</sub> = 0.25，R <sub>SII</sub> = 0.24，P &lt;0.05）呈正相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：SIRI和SII是SLE患者疾病活动和肾脏受累的生物标志物，可用于评估和预测SLE的发生，疾病活动和狼疮性肾炎的发生评估。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39958362/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">39958362</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11825474/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">PMC11825474</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1530534>10.3389/fimmu.2025.1530534</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39958362</guid><pubDate> Mon, 17 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Chi-Hui Yang</dc:creator><dc:creator> Xin-yi Wang</dc:creator><dc:creator> Yi-Hui Zhang</dc:creator><dc:creator>宁丁</dc:creator><dc:date>2025-02-17</dc:date><dc:source>免疫学领域</dc:source><dc:title>Siri和Sii作为全身性红斑狼疮中疾病活动和狼疮肾炎的潜在生物标志物</dc:title><dc:identifier>PMID：39958362</dc:identifier><dc:identifier> PMC：PMC11825474</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1530534</dc:identifier></item><item><title>病例报告：肝细胞癌治疗诱导的1型糖尿病患有糖尿病性酮症酸中毒的病例</title><link/>https://pubmed.ncbi.nlm.nih.gov/39958361/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250217194921&amp;v=2.18.0.post9+e462414<description>该病例报告提出了一名57岁的肝细胞癌男性，患有1型糖尿病（T1DM）和糖尿病性酮症酸中毒（DKA）（DKA），在用Envafolimab（PD-L1免疫检查点抑制剂）治疗后。几个周期的Envafolimab周期后，患者经历了高血糖和DKA的快速发作，这与免疫检查点抑制剂（ICIS）诱导的糖尿病模式一致。值得注意的是，缺乏与糖尿病相关的自身抗体表明糖尿病... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月28日； 16：1505195。 doi：10.3389/fimmu.2025.1505195。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">该病例报告提出了一名57岁的肝细胞癌男性，患有1型糖尿病（T1DM）和糖尿病性酮症酸中毒（DKA）（DKA），在用Envafolimab（PD-L1免疫检查点抑制剂）治疗后。几个周期的Envafolimab周期后，患者经历了高血糖和DKA的快速发作，这与免疫检查点抑制剂（ICIS）诱导的糖尿病模式一致。值得注意的是，与糖尿病相关的自身抗体的缺乏表明，糖尿病是由Envafolimab的免疫调节作用而不是预先存在的自身免疫性疾病引起的。管理需要强化的胰岛素治疗和一种稳定患者健康的多学科方法。该病例强调了提高临床意识和早期干预的关键需求，以管理与Envafolimab（如Envafolimab）相关的严重免疫相关不良事件（IRAE）。自身免疫相关的不良事件的复杂性，例如在我们的患者中观察到的负自身免疫性特征，强调了多学科协作以优化患者结果的重要性。我们主张制定长期的随访计划，包括定期监测潜在的IRAES和内分泌功能评估，以解决ICI治疗后疾病的长期性。认识到当前理解的局限性，明确呼吁进行进一步的研究，特别是在识别可能预测免疫疗法不良反应的生物标志物方面，以指导精确医学并提高患者的安全性。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39958361/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">39958361</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11827420/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">PMC11827420</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1505195>10.3389/fimmu.2025.1505195</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39958361</guid><pubDate> Mon, 17 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Youjia li</dc:creator><dc:creator> Kai Qu</dc:creator><dc:creator> xiuli li</dc:creator><dc:creator> Xin Yang</dc:creator><dc:creator> Kanghuai Zhang</dc:creator><dc:creator> jao Xie</dc:creator><dc:date> 2025-02-17</dc:date><dc:source>免疫学领域</dc:source><dc:title>病例报告：肝细胞癌治疗诱导的1型糖尿病患有糖尿病性酮症酸中毒的病例</dc:title><dc:identifier>PMID：39958361</dc:identifier><dc:identifier> PMC：PMC11827420</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1505195</dc:identifier></item><item><title> Ninjurin1在免疫，细胞死亡和疾病中的多方面作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/39958360/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250217194921&amp;v=2.18.0.post9+e462414<description> Ninjurin1（Ninj1）最初被鉴定为神经损伤诱导的粘附分子，可促进轴突生长。最初，它的特征是促进神经再生并介导与神经炎症相关的单核细胞/巨噬细胞的跨内皮转运。最近的证据表明，NINJ1在裂解细胞死亡中介导质膜破裂（PMR）。 NINJ1的不存在或抑制会延迟PMR，从而减轻细胞裂解引起的炎症的扩散... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月31日； 16：1519519。 doi：10.3389/fimmu.2025.1519519。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Ninjurin1（Ninj1）最初被鉴定为神经损伤诱导的粘附分子，可促进轴突生长。最初，它的特征是促进神经再生并介导与神经炎症相关的单核细胞/巨噬细胞的跨内皮转运。最近的证据表明，NINJ1在裂解细胞死亡中介导质膜破裂（PMR）。 NINJ1的不存在或抑制会延迟PMR，从而减轻细胞裂解引起的炎症的扩散并防止各种细胞死亡相关的病理的进展，这表明在这些过程中有保守的调节机制。进一步的研究阐明了NINJ1介导的PMR的结构基础和机制。尽管建立了NINJ1在PMR中的作用，但其激活因素的身份及其对疾病的影响仍有待充分的探索。这篇综述综合了有关NINJ1介导的PMR的结构基础和机制的当前知识，并讨论了其在炎症性疾病，神经系统疾病，癌症和血管损伤中的重要性和治疗靶向潜力。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39958360/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">39958360</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11825492/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">PMC11825492</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1519519>10.3389/fimmu.2025.1519519</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39958360</guid><pubDate> Mon, 17 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Lili Zhu</dc:creator><dc:creator> Yunfei Xu</dc:creator><dc:date> 2025-02-17</dc:date><dc:source>免疫学领域</dc:source><dc:title>Ninjurin1在免疫，细胞死亡和疾病中的多方面作用</dc:title><dc:identifier>PMID：39958360</dc:identifier><dc:identifier> PMC：PMC11825492</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1519519</dc:identifier></item><item><title>肠道菌群与结直肠癌之间免疫细胞关联的基因预测：孟德尔随机研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/39958359/？ 4<description>结论：我们的中介MR分析提供了遗传证据，表明循环免疫细胞可能介导肠道菌群与CRC之间的因果关系。确定的关联和调解效应为CRC的潜在治疗途径提供了新的见解。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月31日； 16：1460936。 doi：10.3389/fimmu.2025.1460936。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：越来越多的研究表明，肠道微生物群会影响大肠癌（CRC）的发展和发展。但是，两者之间是否存在因果关系仍然不清楚，而在这种情况下，免疫细胞的作用尚不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：阐明肠道菌群与CRC之间的因果关系，并探索循环免疫细胞的潜在介导作用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">材料和方法：为了分析肠道微生物群和CRC之间的因果关系，我们采用了单变量的孟德尔随机化方法（UVMR）方法。随后，两步的多变量孟德尔随机化（MVMR）评估循环免疫细胞的潜在介导作用。首先，应用了反相位加权方法来评估暴露与结果之间的因果关系。为了确保连接肠道微生物群和CRC的结果的鲁棒性，我们使用强大的反相位加权，受惩罚的反相位加权和惩罚强大的反相位加权方法验证了发现。此外，我们采用了先生的截距，以减轻水平多效性的影响。 MR-Presso用于通过排除异常仪器变量来检测和纠正异常值。最后，我们通过贝叶斯加权孟德尔随机化（BWMR），最大样本，套索，偏见，逆差异加权和污染混合物等方法来补充分析，以建立强大而引人注目的因果关系。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在考虑了反向因果关系，水平多效性和各种方法校正之后，<i>双歧杆菌喀什瓦诺克斯（Kashiwanohense）</i> ， <i>GCA-900066755 SP900066755</i> ， <i>geminocypystis</i>和saccharofermentanaceae表现出强大而鲁棒的car含量对CRC的影响。具体而言，单核细胞上的CD40（2.82％）和CD33 <sup>+</sup> HLA -DR + <sup>CD14-</sup>细胞（12.87％）的CD40介导了<i>双歧杆菌kashiwanohense</i>与CRC风险之间的因果关系。此外，CD33上的CD45 <sup>-</sup> HLA-DR <sup>+</sup> （3.94％）介导了<i>GCA-900066755 SP900066755</i>与CRC风险之间的因果关系。此外，终端分化的CD4 <sup>+</sup> T细胞（11.55％）介导了<i>GEMINOCYSTIS</i>与CRC风险之间的因果关系。最后，单核细胞（2.35％），中央记忆CD4 <sup>+</sup> T细胞（5.76％）和CD28 <sup>+</sup> CD45RA + CD45RA <sup>+</sup> CD8 <sup>+</sup> T细胞（5.00％）上的CD40（5.76％）和CD28介导了糖含量和CRC风险之间的因果关系。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们的中介MR分析提供了遗传证据，表明循环免疫细胞可能介导肠道菌群与CRC之间的因果关系。确定的关联和调解效应为CRC的潜在治疗途径提供了新的见解。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39958359/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">39958359</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11825486/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">PMC11825486</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1460936>10.3389/fimmu.2025.1460936</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39958359</guid><pubDate> Mon, 17 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Yan Zhong</dc:creator><dc:creator>广氏陈</dc:creator><dc:creator>Menglu Chen</dc:creator><dc:creator> Junsong Cui</dc:creator><dc:creator> Qianren tan</dc:creator><dc:creator> Zhenghua Xiao</dc:creator><dc:date> 2025-02-17</dc:date><dc:source>免疫学领域</dc:source><dc:title>肠道菌群与结直肠癌之间免疫细胞关联的基因预测：孟德尔随机研究</dc:title><dc:identifier>PMID：39958359</dc:identifier><dc:identifier> PMC：PMC11825486</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1460936</dc:identifier></item><item><title> PD-L1敲除或ZG16过表达抑制PDAC的进展并调节TAM极化</title><link/>https://pubmed.ncbi.nlm.nih.gov/39958358/？ 4<description> CRISPR/CAS9介导的基因组编辑有可能在细胞表面和细胞内部删除PD-L1，从而抑制肿瘤的生长和迁移并克服免疫抑制。具有凝集素结构的ZG16可以降低细胞表面上的PD-L1表达。但是，尚未研究胰腺导管腺癌（PDAC）细胞中PD-L1表达的两种方法的直接比较。在这项研究中，我们建立了两个Panc-1细胞系：一个带有PD-L1敲除... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月31日； 16：1510179。 doi：10.3389/fimmu.2025.1510179。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CRISPR/CAS9介导的基因组编辑有可能在细胞表面和细胞内部删除PD-L1，从而抑制肿瘤的生长和迁移并克服免疫抑制。具有凝集素结构的ZG16可以降低细胞表面上的PD-L1表达。但是，尚未研究胰腺导管腺癌（PDAC）细胞中PD-L1表达的两种方法的直接比较。在这项研究中，我们建立了两个PANC-1细胞系：一个具有PD-L1敲除，另一个具有ZG16过表达。两种方法都促进了与M1表型的肿瘤相关巨噬细胞（TAM）的极化，如M1标记CD11C+<i>体外</i>和<i>体内</i>的水平增加所示。同时，我们观察到M2标记CD206+的降低，免疫激活相关的细胞因子/趋化因子的上调以及免疫抑制细胞因子和肿瘤血管生成因子的降低。总而言之，PD-L1敲除和ZG16的过表达代表了PDAC处理的有希望的方法。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39958358/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">39958358</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11826313/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">PMC11826313</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1510179>10.3389/fimmu.2025.1510179</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39958358</guid><pubDate> Mon, 17 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Hui Meng</dc:creator><dc:creator>曼曼南</dc:creator><dc:creator>Yizhen li</dc:creator><dc:creator> yi ding</dc:creator><dc:creator> Xiaokun fang</dc:creator><dc:creator> Weiqian MA</dc:creator><dc:creator> Mingzhi Zhang</dc:creator><dc:date> 2025-02-17</dc:date><dc:source>免疫学领域</dc:source><dc:title>PD-L1敲除或ZG16过表达抑制PDAC的进展并调节TAM极化</dc:title><dc:identifier>PMID：39958358</dc:identifier><dc:identifier> PMC：PMC11826313</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1510179</dc:identifier></item><item><title>来自不同方式的生物标志物组合预测多发性硬化症的早期残疾积累</title><link/>https://pubmed.ncbi.nlm.nih.gov/39958357/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250217194921&amp;v=2.18.0.post9+e462414<description>结论：多模式生物标志物，即源自MRI，OCT和血液的不同主要病理替代物，告知疾病病理的不同部位，导致临床进展。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月31日； 16：1532660。 doi：10.3389/fimmu.2025.1532660。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：建立生物标志物来预测多发性硬化症（MS）障碍应计的挑战，这可能是由于神经炎症和神经变性的复杂相互作用所致。在这里，我们旨在研究单个和多模式生物标志物组合的预后价值，以预测MS患者的四年残疾进展。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：根据扩大的残疾状态量表（EDSS），总共随访了111名MS患者四年以跟踪残疾积累。三种临床相关的方式（MRI，OCT和血清）是疾病恶化的潜在预测因子的来源。确定了每种方式的两种关键措施，并与随后的残疾进展有关：病变体积（LV），灰质体积（GMV），视网膜神经纤维层，神经节细胞内的丛状丛层，血清神经丝光链（SNFL）和血清Glial原纤维酸性蛋白。首先，进行了接收器操作员特征（ROC）分析，以识别单个生物标志物及其组合的判别能力。其次，我们将结构方程建模（SEM）应用于单个生物标志物，以确定其因果关系之间的关系。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：基线GMV本身允许基于ROC分析鉴定随后的EDSS进展。所有其他单独的基线生物标志物都无法自行区分进步和非促进患者。在比较所有可能的生物标志物组合时，MRI，OCT和血液生物标志物的三方组合达到了最高的判别精度。最后，预测因果模型确定LV介导GMV和SNFL对残疾进展的影响的重要部分。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：多模式生物标志物，即源自MRI，OCT和血液的不同主要病理替代物，告知疾病病理的不同部位，导致临床进展。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39958357/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">39958357</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11825316/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">PMC11825316</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1532660>10.3389/fimmu.2025.1532660</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39958357</guid><pubDate> Mon, 17 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Vinzenz Fleischer</dc:creator><dc:creator> Tobias Brummer</dc:creator><dc:creator> Muthuraman Muthuraman</dc:creator><dc:creator>福克·斯特芬（Falk Steffen）</dc:creator><dc:creator> Milena Heldt</dc:creator><dc:creator>玛丽亚·普罗帕帕（Maria Protopapa）</dc:creator><dc:creator>穆里尔·施拉德（Muriel Schraad）</dc:creator><dc:creator> Gabriel Gonzalez-Escamilla</dc:creator><dc:creator> Sergiu Groppa</dc:creator><dc:creator> Stefan Bittner</dc:creator><dc:creator>弗劳克·齐普（Frauke Zipp）</dc:creator><dc:date> 2025-02-17</dc:date><dc:source>免疫学领域</dc:source><dc:title>来自不同方式的生物标志物组合预测多发性硬化症的早期残疾积累</dc:title><dc:identifier>PMID：39958357</dc:identifier><dc:identifier> PMC：PMC11825316</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1532660</dc:identifier></item><item><title>在促进性大的B细胞淋巴瘤患者的嵌合抗原受体T细胞治疗之前，进行桥接放射治疗的结果</title><link/>https://pubmed.ncbi.nlm.nih.gov/39958356/？ 4<description>结论：BRT和CART对于精选的侵袭性B细胞淋巴瘤患者来说是一个很好的治疗策略。包括所有疾病部位（包括所有疾病部位）的全面BRT与改善的预后有关。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月31日； 16：1517348。 doi：10.3389/fimmu.2025.1517348。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：在抗CD19定向的嵌合抗原受体T细胞疗法（CAR-T）之前，精选的患有复发/难治性攻击性B细胞淋巴瘤的患者可能受益于桥接辐射（BRT）。在这里，我们检查了与BRT和CAR-T之后的结果和失败模式相关的患者和治疗因素。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们回顾性地审查了弥漫性大B细胞淋巴瘤（DLBCL），他们在Axicabtagene Cileleucel，Tisagenlecleucel或Lisocabtagene Maraleucel之前接受了BRT，在11/2017-4/2023之间。提取了临床/治疗特征，反应和毒性。使用Kaplan-Meier或Cox回归模型对生存进行建模，以用于随时间分布的事件，或用于疾病反应的二元逻辑回归。使用了Fisher的精确测试或Mann-Whitney U方法。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在51例患者中，有25.5％的患者患有笨重的疾病，而64.7％的患者患有III/IV期疾病。仅将所有疾病部位的BRT全面分配给了51％的患者，而29.4％的患者则被全身治疗。中位随访时间为10.3个月（95％CI：7.7-16.4）。在输注后30天时，总体应答率（ORR）为82.4％。总体生存期（OS）中位数为22.1个月（6.6个未达到），无进展生存期（PFS）为7.4个月（5.5-30）。 1年的OS/PF分别为80％（66-99）/78％（64-87），分别为59％（44-71）/54％（40-67），分别为2年。所有疾病部位的全面RT与改善的PFS和OS相关， <i>P≤0.04</i> 。另外，ECOG≥2和III/IV期疾病预测OS差（ <i>P≤0.02</i> ）。疾病大量，IPI≥3和非GCB组织学是疾病特异性生存（DSS）的预测因子较差， <i>p</i> &lt;0.05。后两个以及BRT剂量≤30Gy预测PFS较差（ <i>P</i> &lt;0.05）。<i>在患有晚期疾病的患者中，与局灶性BRT相比（n</i> <i>=</i> 23）， <i>p</i> >; 0.17，所有疾病的全面BRT与OS和PFS的改善无关。在桥接RT与Chemort中没有差异。 26例患者出现复发（50.9％），其中46％是现场。现场复发的风险与笨重的疾病相关（OR = 7，95％CI：1.2-41， <i>p</i> = 0.03），并在30天后评估时缺乏反应（OR = 16.8，95％CI：1.6 -176， <i>p</i> = 0.02），但没有BRT剂量（ <i>p</i> = 0.27）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: bRT and CART is a good treatment strategy for select patients with aggressive B cell lymphoma. Comprehensive bRT including all sites of disease is associated with improved outcomes.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39958356/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">39958356</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11825444/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">PMC11825444</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1517348>10.3389/fimmu.2025.1517348</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39958356</guid><pubDate> Mon, 17 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Gohar S Manzar</dc:creator><dc:creator> Chelsea C Pinnix</dc:creator><dc:creator> Stephanie O Dudzinski</dc:creator><dc:creator> Kathryn E Marqueen</dc:creator><dc:creator> Elaine E Cha</dc:creator><dc:creator> Lewis F Nasr</dc:creator><dc:creator> Alison K Yoder</dc:creator><dc:creator> Michael K Rooney</dc:creator><dc:creator> Paolo Strati</dc:creator><dc:creator> Sairah Ahmed</dc:creator><dc:creator> Chijioke Nze</dc:creator><dc:creator> Ranjit Nair</dc:creator><dc:creator> Luis E Fayad</dc:creator><dc:creator>迈克尔·王</dc:creator><dc:creator>Loretta J Nastoupil</dc:creator><dc:creator> Jason R Westin</dc:creator><dc:creator> Christopher R Flowers</dc:creator><dc:creator> Sattva S Neelapu</dc:creator><dc:creator> Jillian R Gunther</dc:creator><dc:creator> Bouthaina S Dabaja</dc:creator><dc:creator> Susan Y Wu</dc:creator><dc:creator> Penny Q Fang</dc:creator><dc:date> 2025-02-17</dc:date><dc:source> Frontiers in immunology</dc:source><dc:title> Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas</dc:title><dc:identifier> pmid:39958356</dc:identifier><dc:identifier> pmc:PMC11825444</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1517348</dc:identifier></item><item><title> A preoperative predictive model based on multi-modal features to predict pathological complete response after neoadjuvant chemoimmunotherapy in esophageal cancer patients</title><link/> https://pubmed.ncbi.nlm.nih.gov/39958355/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250217194921&amp;v=2.18.0.post9+e462414<description> CONCLUSIONS: The combined multi-modality model we propose can better predict the pCR status of esophageal cancer and help inform clinical treatment decisions. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Front Immunol</b> . 2025 Jan 27;16:1530279. doi: 10.3389/fimmu.2025.1530279. eCollection 2025.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: This study aimed to develop a multi-modality model by incorporating pretreatment computed tomography (CT) radiomics and pathomics features along with clinical variables to predict pathologic complete response (pCR) to neoadjuvant chemoimmunotherapy in patients with locally advanced esophageal cancer (EC). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHOD: A total of 223 EC patients who underwent neoadjuvant chemoimmunotherapy followed by surgical intervention between August 2021 and December 2023 were included in this study. Radiomics features were extracted from contrast-enhanced CT images using PyrRadiomics, while pathomics features were derived from whole-slide images (WSIs) of pathological specimens using a fine-tuned deep learning model (ResNet-50). After feature selection, three single-modality prediction models and a combined multi-modality model integrating two radiomics features, 11 pathomics features, and two clinicopathological features were constructed using the support vector machine (SVM) algorithm. The performance of the models were evaluated using receiver operating characteristic (ROC) analysis, calibration plots, and decision curve analysis (DCA). Shapley values were also utilized to explain the prediction model. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: The predictive capability of the multi-modality model in predicting pCR yielded an area under the curve (AUC) of 0.89 (95% confidence interval [CI], 0.75-1.00), outperforming the radiomics model (AUC 0.70 [95% CI 0.54-0.85]), pathomics model (AUC 0.77 [95% CI 0.53-1.00]), and clinical model (AUC 0.63 [95% CI 0.46-0.80]). Additionally, both the calibration plot and DCA curves support the clinical utility of the integrated multi-modality model. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: The combined multi-modality model we propose can better predict the pCR status of esophageal cancer and help inform clinical treatment decisions.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39958355/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">39958355</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11827421/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">PMC11827421</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1530279>10.3389/fimmu.2025.1530279</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39958355</guid><pubDate> Mon, 17 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Yana Qi</dc:creator><dc:creator> Yanran Hu</dc:creator><dc:creator> Chengting Lin</dc:creator><dc:creator> GE歌曲</dc:creator><dc:creator>Liting Shi</dc:creator><dc:creator> Hui Zhu</dc:creator><dc:date> 2025-02-17</dc:date><dc:source> Frontiers in immunology</dc:source><dc:title> A preoperative predictive model based on multi-modal features to predict pathological complete response after neoadjuvant chemoimmunotherapy in esophageal cancer patients</dc:title><dc:identifier> pmid:39958355</dc:identifier><dc:identifier> pmc:PMC11827421</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1530279</dc:identifier></item><item><title> Case report: Novel multi-exon homozygous deletion of &lt;em>;ZBTB24&lt;/em>; causes immunodeficiency, centromeric instability, and facial anomalies syndrome 2</title><link/> https://pubmed.ncbi.nlm.nih.gov/39958354/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250217194921&amp;v=2.18.0.post9+e462414<description> Immunodeficiency, centromeric instability, and facial anomalies syndrome (ICF) is a rare genetic disease characterized by hypogammaglobulinemia, T cell immune deficiency with age, pericentromeric hypomethylation, facial abnormalities, and intellectual disability. This study aimed to investigate the phenotype and immune function of a girl with ICF2, identify her genetic defect, and explore the potential pathogenic mechanisms of the disease. We identified a homologous deletion mutation in this... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Front Immunol</b> . 2025 Jan 31;16:1517417. doi: 10.3389/fimmu.2025.1517417. eCollection 2025.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Immunodeficiency, centromeric instability, and facial anomalies syndrome (ICF) is a rare genetic disease characterized by hypogammaglobulinemia, T cell immune deficiency with age, pericentromeric hypomethylation, facial abnormalities, and intellectual disability. This study aimed to investigate the phenotype and immune function of a girl with ICF2, identify her genetic defect, and explore the potential pathogenic mechanisms of the disease. We identified a homologous deletion mutation in this girl, which involves exons 1-5 and part of introns 1 and 6 of the <i>ZBTB24</i> gene (NG_029388.1: g.2831_18,995del). This <i>ZBTB24</i> variant produces a severely truncated ZBTB24 protein that lacks the BTB, AT hook and eight zinc fingers. The above changes may lead to abnormal transcriptional function of the ZBTB24 protein. Karyotype analysis showed fragile sites and entire arm deletions were detected on chromosomes 1 and 16 and triradials on chromosome 16. The novel multi-exon deletion of <i>ZBTB24</i> causes immunodeficiency, severe pneumonia and centromeric instability in the patient. During the follow-up, the patient&#39;s pneumonia continued to progress despite receiving intravenous immunoglobulin (IVIG) replacement and anti-infective therapy. These results indicated that this novel multi-exon deletion variant of <i>ZBTB24</i> may be the genetic etiology of ICF2. The discovery of this novel mutation expands the mutation spectrum of the <i>ZBTB24</i> gene and improves our understanding of the molecular mechanisms underlying ICF.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39958354/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">39958354</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11825828/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">PMC11825828</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1517417>10.3389/fimmu.2025.1517417</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39958354</guid><pubDate> Mon, 17 Feb 2025 06:00:00 -0500</pubDate><dc:creator> YAN LONG</dc:creator><dc:creator> Chenghan Wang</dc:creator><dc:creator> Jie Xiao</dc:creator><dc:creator> Yunhua Huang</dc:creator><dc:creator> Xiaoting Ling</dc:creator><dc:creator> Chaoyu Huang</dc:creator><dc:creator> ying陈</dc:creator><dc:creator>Jiaqi Luo</dc:creator><dc:creator> Rongheng Tang</dc:creator><dc:creator> Faquan Lin</dc:creator><dc:creator> Yifang Huang</dc:creator><dc:date> 2025-02-17</dc:date><dc:source> Frontiers in immunology</dc:source><dc:title> Case report: Novel multi-exon homozygous deletion of &lt;em>;ZBTB24&lt;/em>; causes immunodeficiency, centromeric instability, and facial anomalies syndrome 2</dc:title><dc:identifier> pmid:39958354</dc:identifier><dc:identifier> pmc:PMC11825828</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1517417</dc:identifier></item><item><title> A novel approach to digital characterisation of Tertiary Lymphoid Structures in colorectal cancer</title><link/> https://pubmed.ncbi.nlm.nih.gov/39958353/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250217194921&amp;v=2.18.0.post9+e462414<description> INTRODUCTION: Tertiary Lymphoid Structures (TLS) in cancer tissue are potential sites for the organisation of immune responses to cancer, and correlate positively with improved clinical outcomes for patients including in colorectal cancer (CRC). However it has proven challenging to standardise assessment of TLS due to the highly variable appearances of circumscribed domains of TLS within tissue sections. A recent three-dimensional reconstruction of TLS in CRC tissue showed that TLS are often... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Front Immunol</b> . 2025 Jan 28;16:1500792. doi: 10.3389/fimmu.2025.1500792. eCollection 2025.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> INTRODUCTION: Tertiary Lymphoid Structures (TLS) in cancer tissue are potential sites for the organisation of immune responses to cancer, and correlate positively with improved clinical outcomes for patients including in colorectal cancer (CRC). However it has proven challenging to standardise assessment of TLS due to the highly variable appearances of circumscribed domains of TLS within tissue sections. A recent three-dimensional reconstruction of TLS in CRC tissue showed that TLS are often large, multi-lobular structures, suggesting that assessing TLS across whole sections may be necessary to provide an accurate view of TLS activity in a patient&#39;s tumour. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: We used whole-section scans of multiplexed immunofluorescence images to characterise TLS from 22 subjects with CRC. Multiplexed staining for CD20, CD3, CD8, Foxp3 and Ki-67 enabled us to identify B-cells, CD8+ T-cells, Foxp3- CD4 T-cells, and Foxp3+ CD4 Tcells in all sections, and quantify both the presence of these cell subsets in lymphocytic clusters and their degree of proliferation within those clusters. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: In total we identified 524 lymphocytic clusters with morphology consistent with TLS. TLS domains varied substantially between samples in size, morphology, cellular constituents, count (from 4 to 100), and proportion of total section area they occupied (0.2%-7.8%). We quantified proliferation of B-cells and T-cell subsets within TLS domains across entire sections and compared data to the canonical approach of counting and phenotyping individual TLS domains. The whole-slide approach proved simpler, generating digital summaries that readily identified patients with strikingly different levels of immune activity within their TLS. Strong correlations were observed between the proliferation of B-cells and T-cell subsets. The presence of non-proliferating Foxp3+ CD4 T-cells within TLS showed no correlation with the level of proliferation of other lymphocyte subsets. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> DISCUSSION: Whole-section digital quantification of immune cell activity within TLS has advantages over canonical approaches, and could accelerate research into correlations between TLS status and clinical outcomes, with potential to enable a standardised assay for clinical use.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39958353/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">39958353</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11827424/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">PMC11827424</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1500792>10.3389/fimmu.2025.1500792</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39958353</guid><pubDate> Mon, 17 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Luis Munoz-Erazo</dc:creator><dc:creator> Saem Mul Park</dc:creator><dc:creator> Shelly Lin</dc:creator><dc:creator> Chun-Jen J Chen</dc:creator><dc:creator> Lisa YY Zhou</dc:creator><dc:creator> Janet L Rhodes</dc:creator><dc:creator> Taesung Jeon</dc:creator><dc:creator> Sonya Fenton</dc:creator><dc:creator> John L McCall</dc:creator><dc:creator> Roslyn A Kemp</dc:creator><dc:creator> P Rod Dunbar</dc:creator><dc:date> 2025-02-17</dc:date><dc:source> Frontiers in immunology</dc:source><dc:title> A novel approach to digital characterisation of Tertiary Lymphoid Structures in colorectal cancer</dc:title><dc:identifier> pmid:39958353</dc:identifier><dc:identifier> pmc:PMC11827424</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1500792</dc:identifier></item><item><title> Structural engineering of stabilized, expanded epitope nanoparticle vaccines for HPV</title><link/> https://pubmed.ncbi.nlm.nih.gov/39958352/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250217194921&amp;v=2.18.0.post9+e462414<description> Oncogenic forms of HPV account for 4.5% of the global cancer burden worldwide. This includes cervical, vaginal, vulvar, penile, and anal cancers, as well as head and neck cancers. As such, there is an urgent need to develop effective therapeutic vaccines to drive the immune system&#39;s cellular response against cancer cells. One of the primary goals of cancer vaccination is to increase the potency and diversity of anti-tumor T-cell responses; one strategy to do so involves the delivery of... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Front Immunol</b> . 2025 Jan 31;16:1535261. doi: 10.3389/fimmu.2025.1535261. eCollection 2025.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Oncogenic forms of HPV account for 4.5% of the global cancer burden worldwide. This includes cervical, vaginal, vulvar, penile, and anal cancers, as well as head and neck cancers. As such, there is an urgent need to develop effective therapeutic vaccines to drive the immune system&#39;s cellular response against cancer cells. One of the primary goals of cancer vaccination is to increase the potency and diversity of anti-tumor T-cell responses; one strategy to do so involves the delivery of full-length cancer antigens scaffolded onto DNA-launched nanoparticles to improve T-cell priming. We developed a platform, making use of structural prediction algorithms such as AlphaFold2, to design stabilized, more full-length antigens of relevant HPV proteins and then display them on nanoparticles. We demonstrated that many such designs for both the HPV16 E6 and E7 antigens assembled and drove strong CD8+ T-cell responses in mice. We further tested nanoparticles in a genetically diverse, more translationally relevant CD-1 mouse model and demonstrated that both E6 and E7 nanoparticle designs drove a CD8+ biased T-cell response. These findings serve as a proof-of-concept study for nanoparticle antigen design as well as identify new vaccine candidates for HPV-associated cancers.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39958352/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">39958352</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11826081/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250217194921&v=2.18.0.post9+e462414">PMC11826081</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1535261>10.3389/fimmu.2025.1535261</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39958352</guid><pubDate> Mon, 17 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Michaela Helble</dc:creator><dc:creator> Xizhou Zhu</dc:creator><dc:creator> Pratik S Bhojnagarwala</dc:creator><dc:creator> Kevin Liaw</dc:creator><dc:creator> Yangcheng Gao</dc:creator><dc:creator> Amber Kim</dc:creator><dc:creator> Kelly Bayruns</dc:creator><dc:creator> Madison E McCanna</dc:creator><dc:creator> Joyce Park</dc:creator><dc:creator> Kylie M Konrath</dc:creator><dc:creator> Sam Garfinkle</dc:creator><dc:creator> Taylor Brysgel</dc:creator><dc:creator> David B Weiner</dc:creator><dc:creator> Daniel W Kulp</dc:creator><dc:date> 2025-02-17</dc:date><dc:source> Frontiers in immunology</dc:source><dc:title> Structural engineering of stabilized, expanded epitope nanoparticle vaccines for HPV</dc:title><dc:identifier> pmid:39958352</dc:identifier><dc:identifier> pmc:PMC11826081</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1535261</dc:identifier></item></channel></rss>